{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T05:16:03Z","timestamp":1775020563258,"version":"3.50.1"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T00:00:00Z","timestamp":1728864000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Regional Health - Europe"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.lanepe.2024.101112","type":"journal-article","created":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T11:43:25Z","timestamp":1729511005000},"page":"101112","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Gene therapy for spinal muscular atrophy: timing is key"],"prefix":"10.1016","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9270-4061","authenticated-orcid":false,"given":"Laurent","family":"Servais","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lanepe.2024.101112_bib1","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus sham control in infantile-onset spinal muscular atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.lanepe.2024.101112_bib2","doi-asserted-by":"crossref","first-page":"6307","DOI":"10.1007\/s12035-017-0831-9","article-title":"Time is motor neuron: therapeutic window and its correlation with pathogenetic mechanisms in spinal muscular atrophy","volume":"55","author":"Govoni","year":"2018","journal-title":"Mol Neurobiol"},{"key":"10.1016\/j.lanepe.2024.101112_bib3","article-title":"Efficacy and safety of gene therapy with onasemnogene abeparvovec in children with spinal muscular atrophy in the D-A-CH-region: a population-based observational study","volume":"47","author":"Wei\u00df","year":"2024","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.lanepe.2024.101112_bib4","article-title":"Efficacy and safety of onasemnogene abeparvovec in children with spinal muscular atrophy type 1: real-world evidence from six infusion centres in the United Kingdom","volume":"37","author":"Gowda","year":"2024","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.lanepe.2024.101112_bib5","doi-asserted-by":"crossref","unstructured":"Vr\u0161\u010daj E, Dangouloff T, Osredkar D, Servais L. Newborn screening programs for spinal muscular atrophy worldwide in 2023. J Neuromuscular Dis. In press. DOI 10.1177\/22143602241288095.","DOI":"10.1016\/j.nmd.2023.07.275"},{"issue":"7","key":"10.1016\/j.lanepe.2024.101112_bib6","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.3390\/genes14071377","article-title":"Spinal muscular atrophy treatment in patients identified by newborn screening\u2014a systematic review","volume":"14","author":"Aragon-Gawinska","year":"2023","journal-title":"Genes"},{"key":"10.1016\/j.lanepe.2024.101112_bib7","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1001\/jamapediatrics.2024.0492","article-title":"Clinical effectiveness of newborn screening for spinal muscular atrophy: a nonrandomized controlled trial","volume":"178","author":"Schwartz","year":"2024","journal-title":"JAMA Pediatr"},{"issue":"10398","key":"10.1016\/j.lanepe.2024.101112_bib8","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/S0140-6736(23)01281-3","article-title":"Universal newborn screening for spinal muscular atrophy in Ukraine","volume":"402","author":"Olkhovych","year":"2023","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.lanepe.2024.101112_bib9","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1002\/acn3.51889","article-title":"Combination disease-modifying treatment in spinal muscular atrophy: a proposed classification","volume":"10","author":"Proud","year":"2023","journal-title":"Ann Clin Transl Neurol"},{"issue":"1","key":"10.1016\/j.lanepe.2024.101112_bib10","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/dmcn.15286","article-title":"Financial cost and quality of life of patients with spinal muscular atrophy identified by symptoms or newborn screening","volume":"65","author":"Dangouloff","year":"2023","journal-title":"Dev Med Child Neurol"}],"container-title":["The Lancet Regional Health - Europe"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666776224002795?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666776224002795?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T10:14:29Z","timestamp":1733480069000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666776224002795"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":10,"alternative-id":["S2666776224002795"],"URL":"https:\/\/doi.org\/10.1016\/j.lanepe.2024.101112","relation":{},"ISSN":["2666-7762"],"issn-type":[{"value":"2666-7762","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gene therapy for spinal muscular atrophy: timing is key","name":"articletitle","label":"Article Title"},{"value":"The Lancet Regional Health - Europe","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lanepe.2024.101112","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.lanepe.2024.101092","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101112"}}